BACKGROUND: Clinical outcome of vascular bypass surgery using autologous vein graft is limited by neointimal formation associated with vein graft failure. Because inflammatory changes are one of the main pathologic features of vein graft failure, monocyte chemoattractant protein-1 (MCP-1) might therefore underlie in the mechanism of vein graft failure. There is no direct evidence, however, that shows the benefits of local anti-MCP-1 therapy as a novel molecular approach for prevention of vein graft failure. METHODS: To block MCP-1, we used an N-terminal deletion mutant of the MCP-1 gene (7ND), which lacks the N-terminal amino acids 2 to 8, binds to its receptor CCR2, and blocks MCP-1-mediated monocyte chemotaxis. 7ND works as dominant-negative inhibitor of MCP-1. Autologous canine jugular vein grafts were transfected by incubating them ex vivo in a solution with or without adenovirus vectors containing 7ND gene or LacZ gene, and interposed into the carotid arteries. RESULTS: Adenovirus-mediated gene transfer of 7ND, but not LacZ gene transfer, significantly attenuated inflammation (monocyte infiltration per mm2 on day 7: 328+/-59, 220+/-11, 26+/-4 in control, LacZ, and 7ND groups, respectively, P<.05, n=4 each) and proliferation (appearance of proliferating cells per mm2 on day 7: 1005+/-186, 756+/-106, 252+/-27 in control, LacZ, and 7ND groups, P<.05, n=4 each) at 7 days after the operation and thus suppressed neointimal formation (neointimal area in mm2 on day 28: 1.63+/-0.51, 1.96+/-0.48, 0.68+/-0.10 in control, LacZ, and 7ND groups, P<.05, n=4 each). This strategy also attenuated upregulation of MCP-1 activities but did not affect endothelial regeneration process. CONCLUSIONS: Blockade of MCP-1 by adenoviral gene transfer of 7ND limits neointimal formation associated with vein graft failure in dogs. This study highlights the potential therapeutic benefit of local anti-MCP-1 therapy for prevention of neointimal formation associated with vein graft failure.
BACKGROUND: Clinical outcome of vascular bypass surgery using autologous vein graft is limited by neointimal formation associated with vein graft failure. Because inflammatory changes are one of the main pathologic features of vein graft failure, monocyte chemoattractant protein-1 (MCP-1) might therefore underlie in the mechanism of vein graft failure. There is no direct evidence, however, that shows the benefits of local anti-MCP-1 therapy as a novel molecular approach for prevention of vein graft failure. METHODS: To block MCP-1, we used an N-terminal deletion mutant of the MCP-1 gene (7ND), which lacks the N-terminal amino acids 2 to 8, binds to its receptor CCR2, and blocks MCP-1-mediated monocyte chemotaxis. 7ND works as dominant-negative inhibitor of MCP-1. Autologous canine jugular vein grafts were transfected by incubating them ex vivo in a solution with or without adenovirus vectors containing 7ND gene or LacZ gene, and interposed into the carotid arteries. RESULTS: Adenovirus-mediated gene transfer of 7ND, but not LacZ gene transfer, significantly attenuated inflammation (monocyte infiltration per mm2 on day 7: 328+/-59, 220+/-11, 26+/-4 in control, LacZ, and 7ND groups, respectively, P<.05, n=4 each) and proliferation (appearance of proliferating cells per mm2 on day 7: 1005+/-186, 756+/-106, 252+/-27 in control, LacZ, and 7ND groups, P<.05, n=4 each) at 7 days after the operation and thus suppressed neointimal formation (neointimal area in mm2 on day 28: 1.63+/-0.51, 1.96+/-0.48, 0.68+/-0.10 in control, LacZ, and 7ND groups, P<.05, n=4 each). This strategy also attenuated upregulation of MCP-1 activities but did not affect endothelial regeneration process. CONCLUSIONS: Blockade of MCP-1 by adenoviral gene transfer of 7ND limits neointimal formation associated with vein graft failure in dogs. This study highlights the potential therapeutic benefit of local anti-MCP-1 therapy for prevention of neointimal formation associated with vein graft failure.
Authors: Jun-Ichiro Koga; Toshiaki Nakano; James E Dahlman; Jose-Luiz Figueiredo; Hengmin Zhang; Julius Decano; Omar F Khan; Tomiharu Niida; Hiroshi Iwata; Jon C Aster; Hideo Yagita; Daniel G Anderson; C Keith Ozaki; Masanori Aikawa Journal: Arterioscler Thromb Vasc Biol Date: 2015-09-24 Impact factor: 8.311
Authors: Brian L Hoh; Koji Hosaka; Daniel P Downes; Kamil W Nowicki; Cristina E Fernandez; Christopher D Batich; Edward W Scott Journal: Circulation Date: 2011-10-17 Impact factor: 29.690
Authors: Kevin W Southerland; Sarah B Frazier; Dawn E Bowles; Carmelo A Milano; Christopher D Kontos Journal: Transl Res Date: 2012-12-27 Impact factor: 7.012
Authors: Scott M Damrauer; Mark D Fisher; Hiromi Wada; Jeffrey J Siracuse; Cleide G da Silva; Karam Moon; Eva Csizmadia; Elizabeth R Maccariello; Virendra I Patel; Peter Studer; Sanah Essayagh; William C Aird; Soizic Daniel; Christiane Ferran Journal: Atherosclerosis Date: 2010-04-04 Impact factor: 5.162
Authors: Narutoshi Hibino; Tai Yi; Daniel R Duncan; Animesh Rathore; Ethan Dean; Yuji Naito; Alan Dardik; Themis Kyriakides; Joseph Madri; Jordan S Pober; Toshiharu Shinoka; Christopher K Breuer Journal: FASEB J Date: 2011-08-24 Impact factor: 5.191
Authors: Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax Journal: Nat Rev Cardiol Date: 2016-05-19 Impact factor: 32.419